Glycosmedia Weekly Diabetes News - 10/28/2022

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine (The Lancet Diabetes & Endocrinology)

Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel

There were substantial differences in real-world use of glucose-lowering medications across the U.S., Sweden, and Israel, with more optimal pharmacologic management in Israel. Variation in access to care and medication cost across countries may have contributed to these differences. SGLT2i and GLP1RA use in patients at high risk was limited in all three countries during this time period (Diabetes Care)

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019

In this large, population-based study, the magnitude of the association between diabetes and risk of cardiovascular events decreased, while that between CVD and such events remained stable. These results suggest that diabetes is still an important cardiovascular risk factor but no longer equivalent to CVD—a change that likely reflects the use of modern, multifactorial approaches to diabetes (JAMA)

Secular trend for increasing birthweight in offspring of pregnant women with type 1 diabetes: is improved placentation the reason?

Here, we argue that the increase in birthweight is paradoxically related to improved glycaemic control in the pre- and periconceptional periods. Good glycaemic control reduces the prevalence of microangiopathy and improves placentation in early pregnancy, which may lead to unimpeded fetal nutrition (Diabetologia)

Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study

In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels (The Lancet Diabetes & Endocrinology)

Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study

The remission of T2DM after RYGB, SG, and OAGB surgery is dependent on various preoperative factors. Patients with younger age, shorter duration of T2DM, lower preoperative HbA1c and FBS, higher BMI, who were not on insulin therapy, and not having a family history of obesity were the best candidates to achieve a prolonged diabetes remission (BMC Endocrine Disorders)

Association between triglyceride–glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus

The TyG index is significantly associated with NAFLD and shows superior ability for identify NAFLD risk compared with other lipid and glycemic parameters in T2DM (BMC Endocrine Disorders)

MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling

Sixteen microRNAs met the criteria for biomarker selection (Diabetologia)